Member Profile

TLC (Nasdaq: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations. TLC listed on the Nasdaq Global Market (symbol: TLC) in 2018.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   1997 TLC is founded by Dr. Keelung Hong
   2002 Lipo-Dox® is approved for treatment of ovarian cancer
   2004 Lipo-Dox® is approved for treatment of breast cancer
   2012 Publicly listed on Gretai Securities Market in Taiwan on 21 Dec, 2012
   2013 Ampholipad® is approved and launched in Taiwan
   2018 TLC Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
   2018 TLC is listed on the Nasdaq Global Market (symbol: TLC) in 2018
   2020 TLC reports positive results from Phase 2 trial of TLC590 for postsurgical pain
   2020 TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain
   2021 InspirMed™ Inc., a newly established subsidiary that specializes in the development of inhalable liposome formulation programs, such as TLC19, for severe acute and chronic pulmonary diseases.
   2021 TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India.